- Home
- VRDN vs DNTH Comparison
VRDN vs DNTH Comparison
Compare VRDN & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- DNTH
- Stock Information
- Founded
- VRDN 2006
- DNTH 2015
- Country
- VRDN United States
- DNTH United States
- Employees
- VRDN N/A
- DNTH 78
- Industry
- VRDN Medical Specialities
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- VRDN Health Care
- DNTH Health Care
- Exchange
- VRDN Nasdaq
- DNTH Nasdaq
- Market Cap
- VRDN 1.6B
- DNTH 1.4B
- IPO Year
- VRDN N/A
- DNTH N/A
- Fundamental
- Price
- VRDN $23.63
- DNTH $34.98
- Analyst Decision
- VRDN Strong Buy
- DNTH Strong Buy
- Analyst Count
- VRDN 10
- DNTH 11
- Target Price
- VRDN $36.78
- DNTH $65.22
- AVG Volume (30 Days)
- VRDN 1.5M
- DNTH 526.1K
- Earning Date
- VRDN 11-13-2025
- DNTH 11-07-2025
- Dividend Yield
- VRDN N/A
- DNTH N/A
- EPS Growth
- VRDN N/A
- DNTH N/A
- EPS
- VRDN N/A
- DNTH N/A
- Revenue
- VRDN $305,000.00
- DNTH $4,854,000.00
- Revenue This Year
- VRDN N/A
- DNTH N/A
- Revenue Next Year
- VRDN $34,044.63
- DNTH N/A
- P/E Ratio
- VRDN N/A
- DNTH N/A
- Revenue Growth
- VRDN 5.90
- DNTH 17.87
- 52 Week Low
- VRDN $9.90
- DNTH $13.37
- 52 Week High
- VRDN $27.20
- DNTH $40.16
- Technical
- Relative Strength Index (RSI)
- VRDN 62.01
- DNTH 54.07
- Support Level
- VRDN $21.65
- DNTH $32.89
- Resistance Level
- VRDN $24.23
- DNTH $34.50
- Average True Range (ATR)
- VRDN 1.11
- DNTH 1.72
- MACD
- VRDN -0.03
- DNTH -0.24
- Stochastic Oscillator
- VRDN 68.07
- DNTH 41.68
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.